
SOURCE: Fox Business (READ THE LAST TWO PARAGRAPHS)
CVS Caremark, one of the three major pharmacy benefit managers (PBM) in the U.S., stopped coverage for Eli Lilly’s popular weight-loss drug Zepbound, blaming drugs like it for driving up overall plan costs.
Continue reading CVS Caremark Drops Coverage of Popular Weight Loss Drug



